Microbiota Transplantation in Type 2 Diabetes Patients
Study Overview
This study aimed to evaluate the effects of fecal microbiota transplantation (FMT) from healthy lean donors in patients with type 2 diabetes (T2D). It was a phase II clinical trial involving 21 participants (12 men and 9 women) with a mean age of 62.5 years and an average body mass index (BMI) of 32.4 kg/m².
Methods
Participants were divided into three groups: one receiving FMT, another receiving a probiotic (Lactobacillus delbrueckii), and a placebo group. Various health measures were taken at the start, and again at 4 and 12 weeks after treatment.
Results
The study found that:
- FMT did not lead to significant changes in weight, BMI, or blood sugar control (HbA1c levels).
- A slight decrease in uric acid levels was observed in the probiotic group.
- There was a minor increase in HbA1c levels in the FMT group.
Conclusion
In this study, neither FMT from healthy donors nor the probiotic improved insulin sensitivity or blood sugar levels in patients with T2D.
Importance of Clinical Trials
Clinical trials are essential for developing safe and effective treatments. To make their benefits accessible, we introduce DocSym, an AI-driven platform that consolidates medical standards, clinical protocols, and research into one easy-to-use resource for healthcare providers.
Streamlining Healthcare Operations
In today’s healthcare system, efficiency is key. Our mobile apps facilitate scheduling, treatment monitoring, and telemedicine, simplifying patient care management and expanding digital services.
Enhancing Patient Outcomes
By leveraging AI, clinics can improve their workflows, enhance patient care, and reduce reliance on paper processes. Discover more about our solutions at aidevmd.com.
